Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cipla
Colorcon
Fuji
Medtronic
US Army
Citi
Baxter
US Department of Justice
Covington

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,029,533

« Back to Dashboard

Which drugs does patent 9,029,533 protect, and when does it expire?


Patent 9,029,533 protects ICLUSIG and is included in one NDA.

This patent has fifty-three patent family members in seventeen countries.

Summary for Patent: 9,029,533

Title:Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors
Abstract: This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use.
Inventor(s): Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Sharon, MA), Romero; Jan Antoinette C. (Somerville, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Watertown, MA), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA)
Assignee: ARIAD Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/801,116
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF LEUKEMIAS
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► Subscribe A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► Subscribe A METHOD FOR THE TREATMENT OF LEUKEMIAS
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► Subscribe A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,029,533

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,778,942Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors► Subscribe
8,114,874Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors► Subscribe
8,461,167Acetylenic heteroaryl compounds► Subscribe
8,470,851Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors► Subscribe
9,090,561Acetylenic heteroaryl compounds► Subscribe
8,278,307Monocyclic Heteroaryl compounds► Subscribe
9,278,971Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,029,533

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006331673► Subscribe
Australia2007249924► Subscribe
Australia2007249926► Subscribe
BrazilPI0621098► Subscribe
BrazilPI0710328► Subscribe
BrazilPI0710331► Subscribe
Canada2634923► Subscribe
Canada2650273► Subscribe
Canada2651822► Subscribe
China101389338► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
US Army
Novartis
Farmers Insurance
Express Scripts
Harvard Business School
McKinsey
Argus Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot